Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Cambridge biotech Nuclera is on the march globally with its much vaunted benchtop eProtein Discovery system following two ...

Following the installation of eProtein Discovery at leading academic institutes across the UK and Europe 1, the expansion ...

At the recent ELRIG Drug Discovery conference, Technology Networks<i/> spoke with Dr. Kundan Sharma to learn more about how cell-free expression platforms are transforming membrane protein research.

A revolution has occurred in the field of pharmaceutical development due to the development of drugs that target membrane proteins. It is estimated that one-third of currently available drugs target G ...

A research team has developed DeepCodon, a deep learning–based codon optimization tool that significantly improves heterologous protein expression in Escherichia coli while preserving functionally ...

Escherichia coli remains at the forefront of recombinant protein production, owing to its rapid growth, well-characterised genetics and the ease with which it can be genetically manipulated. The ...

This article is based on a poster originally authored by Sunidhi Shetty, Narasimha Murthy Bandaru, Anna Moberg and Marco Manni, which was presented at ELRIG Drug Discovery 2024 in affiliation with ...

More sophisticated biological expression systems expand the functionality of the traditional systems for protein synthesis. Mammalian cells have become the system of choice for antibody production, ...

Advances in mRNA design continue to shape the next generation of therapeutic development. Yet, achieving strong and sustained protein expression remains a persistent challenge across platforms.

The cost-effective, easy-to-use T7 expression system has been integral to Escherichia coli protein production since its introduction in 1986. Now, a just-developed enhancement is making it even better ...